Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada

Trial Profile

Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top